Antisoma plc
http://www.antisoma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Antisoma plc
Breakthroughs, Orphans Hit High Notes As US FDA’s 2020 Novel Approvals Play A Familiar Tune
Influence of expedited review pathways and regulatory incentives is on display in 2020’s novel approvals, which have a composition reassuringly consistent with recent years.
DBV Soars As Path For Peanut Allergy Patch Approval Clears
The French biotech's chances of competing with Aimmune's Palforzia in the peanut allergy market have been boosted after US regulators decided that a fresh Phase III trial for the Viaskin Peanut patch would not be required for resubmission.
Westlake Village BioPartners Closes Two VC Funds Totaling $500m
A $70m fund will back prior investments, while a $430m fund will launch new biotech firms. Harper and Seidenberg tapped into their Amgen connections for the CEO who helms new company Acelyrin.
Alzheimer’s Drug & Dermatitis JAK inhibitor Among New EU Filings
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Xanthus Pharmaceuticals